Initial formation through sale and, following spinout, subsequent venture capital financings and IPO of parent company

Trivascular Technologies, Inc.
1998 - 2014

Our attorneys represented TriVascular, Inc. in its initial formation and in subsequent matters, including several financing rounds; acquisition of key technology; trade secret protection; clinical trial, distribution, patent license, and consulting agreements; and acquisition by Boston Scientific Corporation. Following the spinout of TriVascular from Boston Scientific Corporation, represented TriVascular again, including in connection with multiple venture capital and venture debt financings and all corporate matters, as well as in connection with the initial public offering and Nasdaq Stock Market listing of its parent company, TriVascular Technologies, Inc.

Email Disclaimer